Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy.

Septic shock is the commonest cause of death in intensive care units. Although sepsis usually produces a low systemic vascular resistance and elevated cardiac output, strong evidence (decreased ejection fraction and reduced response to fluid administration) suggests that the ventricular myocardium is depressed and the ventricle dilated. In survivors, these abnormalities are reversible. Failure to develop ventricular dilatation in nonsurvivors suggests that dilatation is a compensatory mechanism needed to maintain adequate cardiac output. With a canine model of septic shock that is very similar to human sepsis, myocardial depression was confirmed using load-independent measures of ventricular performance. Endotoxin administration to humans simulates the qualitative, cardiovascular abnormalities of sepsis. The pathogenesis of septic shock is extraordinarily complex. Diverse microorganisms can generate toxins, stimulating release of potent mediators that act on vasculature and myocardium. A circulating myocardial depressant substance has been closely associated with the myocardial depression of human septic shock. Therapy has emphasized early use of antibiotics, critical care monitoring, aggressive volume resuscitation, and, if shock continues, use of inotropic agents and vasopressors. Pharmacologic or immunologic antagonism of endotoxin or other mediators may prove to enhance survival in this highly lethal syndrome.

[1]  C. Natanson,et al.  Role of endotoxemia in cardiovascular dysfunction and mortality. Escherichia coli and Staphylococcus aureus challenges in a canine model of human septic shock. , 1989, The Journal of clinical investigation.

[2]  J. Kovacs,et al.  The cardiovascular response of normal humans to the administration of endotoxin. , 1989, The New England journal of medicine.

[3]  J. Parrillo,et al.  Promotion and subsequent inhibition of plasminogen activation after administration of intravenous endotoxin to normal subjects. , 1989, The New England journal of medicine.

[4]  J. Shelhamer,et al.  A circulating myocardial depressant substance is associated with cardiac dysfunction and peripheral hypoperfusion (lactic acidemia) in patients with septic shock. , 1989, Chest.

[5]  C. Natanson,et al.  Septic shock: the cardiovascular abnormality and therapy. , 1989, Journal of cardiothoracic anesthesia.

[6]  C. Natanson,et al.  Endotoxin and tumor necrosis factor challenges in dogs simulate the cardiovascular profile of human septic shock , 1989, The Journal of experimental medicine.

[7]  F. Ognibene,et al.  Responses of left ventricular function in survivors and nonsurvivors of septic shock , 1989 .

[8]  M. Haupt,et al.  Impact of critical care physician staffing on patients with septic shock in a university hospital medical intensive care unit. , 1988, JAMA.

[9]  E. Ziegler Protective antibody to endotoxin core: the emperor's new clothes? , 1988, The Journal of infectious diseases.

[10]  J. Edwards,et al.  Reversal of intractable septic shock with norepinephrine therapy. , 1988, Critical care medicine.

[11]  A. Cerami,et al.  Detection of circulating tumor necrosis factor after endotoxin administration. , 1988, The New England journal of medicine.

[12]  F. Ognibene,et al.  Depressed left ventricular performance. Response to volume infusion in patients with sepsis and septic shock. , 1988, Chest.

[13]  W. Hsueh,et al.  Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor. , 1988, The Journal of clinical investigation.

[14]  K. Tracey,et al.  Cachectin: a hormone that triggers acute shock and chronic cachexia. , 1988, The Journal of infectious diseases.

[15]  J. Alouf,et al.  Toxic shock syndrome toxin 1 as an inducer of human tumor necrosis factors and gamma interferon , 1988, The Journal of experimental medicine.

[16]  J. Watters,et al.  Inhibition of cyclo-oxygenase attenuates the metabolic response to endotoxin in humans. , 1988, Archives of surgery.

[17]  K. Tracey,et al.  Cytokine appearance in human endotoxemia and primate bacteremia. , 1988, Surgery, gynecology & obstetrics.

[18]  Kevin J. Tracey,et al.  Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteraemia , 1987, Nature.

[19]  J E Parrillo,et al.  Serial cardiovascular variables in survivors and nonsurvivors of human septic shock: heart rate as an early predictor of prognosis. , 1987, Critical care medicine.

[20]  D. Golenbock,et al.  Lipid X ameliorates pulmonary hypertension and protects sheep from death due to endotoxin , 1987, Infection and immunity.

[21]  T. Clemmer,et al.  A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. , 1987, The New England journal of medicine.

[22]  K. Joiner,et al.  Inhibition of endotoxin-induced priming of human neutrophils by lipid X and 3-Aza-lipid X. , 1987, The Journal of clinical investigation.

[23]  J. Dhainaut,et al.  Coronary hemodynamics and myocardial metabolism of lactate, free fatty acids, glucose, and ketones in patients with septic shock. , 1987, Circulation.

[24]  B. Beutler,et al.  Cachectin: more than a tumor necrosis factor. , 1987, The New England journal of medicine.

[25]  G. Potel,et al.  A reappraisal of norepinephrine therapy in human septic shock , 1987, Critical care medicine.

[26]  C. Natanson,et al.  Gram-negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. , 1986, The Journal of clinical investigation.

[27]  R. Proctor,et al.  Protection of mice against lethal endotoxemia by a lipid A precursor , 1986 .

[28]  B. Meyrick,et al.  Endotoxin and lung injury. , 1986, The American review of respiratory disease.

[29]  C. Natanson,et al.  The coronary circulation in human septic shock. , 1986, Circulation.

[30]  D. Goeddel,et al.  Effect of interleukin 2, interferon-gamma, and mitogens on the production of tumor necrosis factors alpha and beta. , 1985, Journal of immunology.

[31]  B. Beutler,et al.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin. , 1985, Science.

[32]  D. Berman,et al.  Left ventricular performance in septic shock: reversible segmental and global abnormalities. , 1985, American heart journal.

[33]  C. Sprung,et al.  The effects of high-dose corticosteroids in patients with septic shock. A prospective, controlled study. , 1984, The New England journal of medicine.

[34]  E. Cook,et al.  On-site physician staffing in a community hospital intensive care unit. Impact on test and procedure use and on patient outcome. , 1984, JAMA.

[35]  J. Shenep,et al.  Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis. , 1984, The Journal of infectious diseases.

[36]  J. Shelhamer,et al.  Profound but reversible myocardial depression in patients with septic shock. , 1984, Annals of internal medicine.

[37]  J. Parrillo,et al.  Septic shock. Hemodynamics and pathogenesis. , 1983, JAMA.

[38]  C S Bryan,et al.  Analysis of 1,186 episodes of gram-negative bacteremia in non-university hospitals: the effects of antimicrobial therapy. , 1983, Reviews of infectious diseases.

[39]  J. Fierer,et al.  Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli. , 1982, The New England journal of medicine.

[40]  F. Audibert,et al.  Properties of reference Escherichia coli endotoxin and its phthalylated derivative in humans. , 1981, The Journal of infectious diseases.

[41]  W. R. Mccabe,et al.  Gram-negative bacteremia: IV. Re-evaluation of clinical features and treatment in 612 patients , 1980 .

[42]  T. Petty,et al.  Incidence and outcome of the respiratory distress syndrome in gram-negative sepsis. , 1979, Archives of internal medicine.

[43]  A. From,et al.  Polymyxin B sulfate modification of bacterial endotoxin: effects on the development of endotoxin shock in dogs , 1979, Infection and immunity.

[44]  A. M. Lefer,et al.  Isolation of myocardial depressant factor from plasma of dogs in hemorrhagic shock. , 1977, Biochimica et biophysica acta.

[45]  R. Robinson,et al.  Lack of clinical usefulness of the limulus test in the diagnosis of endotoxemia. , 1975, The New England journal of medicine.

[46]  L. Greenfield,et al.  Effects of coronary hypotension and endotoxin on myocardial performance. , 1974, The American journal of physiology.

[47]  S. Wolff Biological effects of bacterial endotoxins in man. , 1973, The Journal of infectious diseases.

[48]  S. Rahimtoola,et al.  Hemodynamic studies and results of therapy in 50 patients with bacteremic shock. , 1973, The American journal of medicine.

[49]  W. R. Mccabe,et al.  Type-specific and cross-reactive antibodies in gram-negative bacteremia. , 1972, The New England journal of medicine.

[50]  L. Greenfield,et al.  Effects of endotoxin on myocardial hemodynamics, performance, and metabolism. , 1971, The American journal of physiology.

[51]  M. Finland,et al.  Changing ecology of bacterial infections as related to antibacterial therapy. , 1970, The Journal of infectious diseases.

[52]  A. M. Lefer,et al.  Origin of myocardial depressant factor in shock. , 1970, The American journal of physiology.

[53]  B. Carroll,et al.  Evaluation of three acute tests of hypothalamic-pituitary-adrenal function. , 1969, Metabolism: clinical and experimental.

[54]  H. Wagner,et al.  The role of endotoxin during typhoid fever and tularemia in man. IV. The integrity of the endotoxin tolerance mechanisms during infection. , 1969, The Journal of clinical investigation.

[55]  J. Ross,et al.  Assessment of Cardiac Function , 1969 .

[56]  D. Rifkind Prevention by polymyxin B of endotoxin lethality in mice , 1967, Journal of bacteriology.

[57]  R. Wilson,et al.  Hemodynamic Measurements in Septic Shock , 1965 .

[58]  M. Weil,et al.  SHOCK CAUSED BY GRAM-NEGATIVE MICROORGANISMS. ANALYSIS OF 169 CASES. , 1964, Annals of internal medicine.

[59]  A. Mauer,et al.  Leukokinetic studies. IV. The total blood, circulating and marginal granulocyte pools and the granulocyte turnover rate in normal subjects. , 1961, The Journal of clinical investigation.

[60]  R. Gilbert Mechanisms of the hemodynamic effects of endotoxin. , 1960, Physiological reviews.

[61]  R. E. Peterson,et al.  Effect of Aspirin and Reserpine on Adrenocortical Response to Piromen in Man , 1956, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.

[62]  M. Weil,et al.  Studies on the circulatory changes in the dog produced by endotoxin from gram-negative microorganisms. , 1956, The Journal of clinical investigation.

[63]  W. Goldring,et al.  HEMODYNAMIC ALTERATIONS IN NORMOTENSIVE AND HYPERTENSIVE SUBJECTS DURING THE PYROGENIC REACTION. , 1945, The Journal of clinical investigation.

[64]  F. Ognibene,et al.  clinical investigations in critical care Right Ventricular Dysfunction and Dilatation , Similar to Left Ventricular Changes , Characterize the Cardiac Depression of Septic Shock in Humans * , 2006 .

[65]  J. Parrillo,et al.  Myocardial dysfunction in sepsis. , 1989, Critical care clinics.

[66]  J. Shelhamer,et al.  Blood histamine concentrations are not elevated in humans with septic shock. , 1989, Critical care medicine.

[67]  S. E. Greisman,et al.  Failure of antisera to J5 and R595 rough mutants to reduce endotoxemic lethality. , 1988, The Journal of infectious diseases.

[68]  W H Schuette,et al.  Closed loop television tracking of beating heart cells in vitro. , 1987, Cytometry.

[69]  D. Morrison,et al.  Endotoxins and disease mechanisms. , 1987, Annual review of medicine.

[70]  A. Fein,et al.  The risk factors, incidence, and prognosis of ARDS following septicemia. , 1983, Chest.

[71]  M. Auclair,et al.  Evidence for an early lipid soluble cardiodepressant factor in rat serum after a sublethal dose of endotoxin. , 1981, Circulatory shock.

[72]  R. J. Baird,et al.  Correlation of the changes in diastolic myocardial tissue pressure and regional coronary blood flow in hemorrhagic and endotoxic shock. , 1978, The Journal of surgical research.

[73]  Weil Mh,et al.  Differences in the mechanism of shock caused by bacterial infections. , 1969 .

[74]  M. Landy,et al.  Quantitative studies of human leukocytic and febrile response to single and repeated doses of purified bacterial endotoxin. , 1962, The Journal of clinical investigation.